Bedaquiline, a diarylquinoline, improved cure rates when added to a multidrug-resistant
tuberculosis (MDR-TB) treatment regimen in a previous placebo-controlled, phase 2 trial …

Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis
(MDR-TB), is recommended for a duration of 24 weeks. There are scarce data on patients …

Bedaquiline is recommended by the World Health Organization for the treatment of
multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We …

Acquired drug resistance by Mycobacterium tuberculosis (MTB) may result in treatment
failure and death. Bedaquiline was recently approved for the treatment of multidrug-resistant …

Treatment of multidrug-resistant tuberculosis (MDR-TB) is hindered by limited efficacy and
significant toxicity of second-line drugs. The need for new therapeutic options is critical to …

Abstract Background In 2012, the Food and Drug Administration approved use of
bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis …

South African patients with rifampicin-resistant tuberculosis (TB) and resistance to
fluoroquinolones and/or injectable drugs (extensively drug-resistant (XDR) and preXDR-TB) …

Bedaquiline is a diarylquinoline antitubercular drug with a novel mechanism of action
against M ycobacterium tuberculosis. Bedaquiline works by inhibiting bacterial adenosine …

Objectives Bedaquiline treatment significantly improves multidrug-resistant tuberculosis
(MDR-TB) patient treatment outcomes. However, safety and efficacy data are lacking for …

Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-
resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and …